Bladder cancer

Bladder cancer detection and classification with Associate Professor of Urology Peter Boström at Turku University Hospital.

Bladder cancer is a cancerous tumor that develops in the lining of the bladder. Worldwide there are over 600,000 new bladder cancer cases every year causing approximately 220,000 deaths. Bladder cancer is also associated with high per patient costs, which are usually upwards from 65,000 dollars per patient. These costs accumulate quickly from invasive procedures that need to be performed to assess how far the cancer has spread when it has been first detected.

AQ Biotech and Turku University Hospital’s joint research study aims to assess AQ Biotech biosensors’ capability to detect and classify bladder cancer from urine samples with the primary target of classifying between non-invasive, invasive and muscle-invasive bladder cancer variants. The biosensor has previously been able to detect and classify prostate cancer from urine samples, and AQ Biotech’s R&D team believes that the same method will also be applicable to bladder cancer detection and classification.